Key points are not available for this paper at this time.
ABSTRACT The parallels between embryonic development and tumorigenesis have reshaped how we conceptualize cancer's molecular foundations. Once viewed as purely mutation‐driven, malignancy is now understood to involve the systematic reactivation of embryonic gene programs—raising a fundamental question: How extensively do tumors co‐opt developmental machinery to sustain their aggressive phenotypes? This review provides a comprehensive synthesis integrating developmental biology, reproductive medicine, and molecular oncology. It systematically examines how tumor cells exploit core developmental machinery, including pluripotency maintenance networks, evolutionarily conserved signaling pathways and epigenetic reprogramming mechanisms, such as DNA methylation, histone modifications, and non‐coding RNA regulation, to acquire stemness properties, drive epithelial‐mesenchymal transition (EMT), remodel the extracellular matrix (ECM), and establish immunosuppressive microenvironments. We further explore germ cell tumor biology, assisted reproductive technology (ART) implications, and DNA damage response vulnerabilities from a developmental perspective. These molecular insights furnish tangible opportunities: biomarker discovery rooted in fetal antigen re‐expression, and therapeutic strategies that selectively disrupt the “embryonic” state of cancer cells while sparing normal tissue. This review synthesizes the core molecular mechanisms connecting embryonic development and tumorigenesis from a multidisciplinary standpoint and outlines future research trajectories and clinical applications, thereby contributing new insights and actionable strategies in the fight against cancer.
Liu et al. (2026) studied this question.